Repare Therapeutics, a preclinical biotech developing gene therapies for solid tumors, raised $220 million by offering 11 million shares at $20, the high end of the upwardly revised range of $18 to $20. On Wednesday, the company raised the proposed IPO range and offer shares to 10 million; it originally planned to offer 7.4 million shares at a range of $16 to $18. Repare Therapeutics plans to list on the Nasdaq under the symbol RPTX. Morgan Stanley, Goldman Sachs, Cowen and Piper Sandler acted as lead managers on the deal.
